{"id":33458,"date":"2018-02-09T12:00:29","date_gmt":"2018-02-09T12:00:29","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=33458"},"modified":"2018-07-21T11:46:03","modified_gmt":"2018-07-21T11:46:03","slug":"09-february-2018-vol-19-no-3","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/33458","title":{"rendered":"09 February 2018: vol 19 no 3"},"content":{"rendered":"<ul>\n<li><strong><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-33477\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2018\/02\/HTB-09-Feb-2018-no-3-cover-209x300.png\" alt=\"\" width=\"188\" height=\"249\" \/><\/strong><a href=\"https:\/\/i-base.info\/htb\/date\/2018\/02\/09\">Contents online<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2018\/02\/HTB-09-Feb-2018-no-3-FINAL-2-column.pdf\" rel=\"noopener\">PDF of this issue<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/forms\/esub.php\">Subscribe by email<\/a><\/li>\n<\/ul>\n<p><strong>The third issue of HTB in 2018 features antiretroviral news, reviews of studies about drug pricing and HIV and pregnancy and two new guidelines online for comment.<\/strong><\/p>\n<p>We lead with approval in the US of the integrase inhibitor bictegravir, in a fixed dose combination (FDC) with emtricitabine and TAF and of a generic FDC using a lower dose of efavirenz.<\/p>\n<p>Regulatory decisions for the EU are expected later this year.<\/p>\n<p>In the UK, pricing is likely to drive access \u2013 when the two largest HIV manufacturers will both have single-pill, once-daily, integrase-based FDCs.<\/p>\n<p>A new review of drug pricing highlights again the difference between manufacturing cost and pricing, even for generic drugs.<\/p>\n<p>We also report the launch of a large new study of ART in pregnancy, that includes dolutegravir, and, notably both TAF and TDF despite a recent (flawed) review in the BMJ calling for a return to AZT. Plus a new review about ART safety, where we also question some of the conclusions.<\/p>\n<p>Two new UK guidelines from BHIVA are online for comment: UK standards of care and the HIV pregnancy guidelines. Both are updating previous versions from five years ago.<\/p>\n<p>Finally, we highlight online resources that bring together a range of interviews, experiences and blogs from diverse activist involved in HIV care.<\/p>\n<p><i>STOP PRESS: plus news that an NHS clinic in London will now prescribe generic PrEP&#8230;<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New ARV approvals, HIV &#038; pregnancy, PrEP in the UK and more&#8230;<\/p>\n","protected":false},"author":3,"featured_media":33483,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-33458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editorial"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/33458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=33458"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/33458\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media\/33483"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=33458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=33458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=33458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}